Drug Trial Radar · NCT02414165
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
Last checked: Nov 20, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
403
Actual
Start
Nov 30, 2015
Primary completion
May 31, 2019
Study completion Dec 20, 2019
Sponsor
- Lead sponsor
- Tocagen Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA. Subjects meeting all of the inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1 ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment with one option of standard of care (Arm SOC). Stratification will be done by IDH1 mutation status. A second stratification factor is based on the patient's Karnofsky Performance Score (KPS) (70-80 vs 90-100). Further, to account for potential differences in treatment choices for the control arm in regions, the trial will be stratified by geographical region during the randomization process. Funding Source - FDA OOPD
Conditions
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
Interventions
Toca 511Biological
Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
Toca FCDrug
Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
LomustineDrug
TemozolomideDrug
BevacizumabBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytomaTime frame: 30 December 2019
Locations
67 sites in 4 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center
Phoenix, Arizona
University of California, Irvine
Irvine, California
University of California San Diego
La Jolla, California
University of California, Los Angeles
Los Angeles, California
St. Joseph Hospital
Orange, California
University of California San Francisco
San Francisco, California
Stanford University
Stanford, California
University of Colorado Cancer Center
Aurora, Colorado
Colorado Neurological Institute
Englewood, Colorado
Associated Neurologists of Southern Connecticut
Fairfield, Connecticut
Yale University/Yale Cancer Center
New Haven, Connecticut
University of Florida McKnight Brain Institute
Gainesville, Florida
University of Miami
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
NorthShore University Health System
Evanston, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Johns Hopkins University School of Medicine
Baltimore, Maryland
University of Michigan
Ann Arbor, Michigan
Henry Ford Health System
Detroit, Michigan
Abbott Northwestern Hospital / Allina Health
Minneapolis, Minnesota
University of Minnesota
Minneapolis, Minnesota
HCA Midwest / Sarah Cannon
Kansas City, Missouri
Washington University St. Louis
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
JFK Medical Center Neuroscience Institute
Edison, New Jersey
John Theurer Cancer Center at Hackensack University
Hackensack, New Jersey
Overlook Medical Center
Summit, New Jersey
North Shore University Hospital
Lake Success, New York
NYU Langone Medical Center
New York, New York
Weill Cornell Medical College
New York, New York
Columbia University
New York, New York
University of Rochester Medical Center
Rochester, New York
Stony Brook University Hospital
Stony Brook, New York
Cincinnati's Children's Hospital Medical Center
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.